Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Core Insights - Atossa Therapeutics is advancing (Z)-endoxifen as a next-generation therapy for metastatic breast cancer, emphasizing its potential to address unmet medical needs in this area [3][11] - The company has enhanced its intellectual property portfolio with three new U.S. patents, bringing the total to over 200 patent claims related to (Z)-endoxifen [1][6] - Atossa ended Q1 2025 with $65.1 million in cash and cash equivalents, maintaining a debt-free status [1] Financial Performance - For Q1 2025, Atossa reported total operating expenses of $7.4 million, an increase of $0.4 million from $7.0 million in Q1 2024 [5][14] - Research and Development (R&D) expenses totaled $4.2 million for Q1 2025, up from $3.7 million in Q1 2024, reflecting an increase of 11% [7][10] - General and Administrative (G&A) expenses were $3.3 million for Q1 2025, slightly up from $3.2 million in Q1 2024, indicating a 1% increase [8][14] Research and Development Focus - Atossa is prioritizing (Z)-endoxifen for metastatic breast cancer, with ongoing clinical trials demonstrating strong tolerability and therapeutic versatility [3][11] - The company is currently evaluating (Z)-endoxifen in three Phase 2 trials targeting different breast cancer types, including ductal carcinoma in situ and estrogen receptor-positive breast cancer [11][12] - The recent patent grants cover various formulations and applications of (Z)-endoxifen, enhancing its market position [6][9] Market Position and Strategy - The strategic focus on metastatic breast cancer reflects Atossa's commitment to addressing significant treatment gaps and the potential for a streamlined regulatory pathway [6][11] - (Z)-endoxifen is positioned as a potentially safer and more effective endocrine therapy, with advantages over current standard-of-care treatments [9][12] - The company aims to unlock the full potential of (Z)-endoxifen while delivering value to shareholders through its robust intellectual property and clinical research programs [3][12]